266 related articles for article (PubMed ID: 35836933)
1. Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer.
Li K; Wang Q; Bian H; Chen Z; He H; Zhao X; Gong P
Front Mol Biosci; 2022; 9():886904. PubMed ID: 35836933
[No Abstract] [Full Text] [Related]
2. Prognostic and immunological role of SERPINH1 in pan-cancer.
Zhong H; Wang Z; Wei X; Liu Y; Huang X; Mo X; Tang W
Front Genet; 2022; 13():900495. PubMed ID: 36105106
[No Abstract] [Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
[TBL] [Abstract][Full Text] [Related]
5. LINC01614 is a promising diagnostic and prognostic marker in HNSC linked to the tumor microenvironment and oncogenic function.
Tian X; Hu D; Wang N; Zhang L; Wang X
Front Genet; 2024; 15():1337525. PubMed ID: 38655053
[TBL] [Abstract][Full Text] [Related]
6. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
Pan T; Wang S; Wang Z
J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
[No Abstract] [Full Text] [Related]
7. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
Front Immunol; 2022; 13():998266. PubMed ID: 36248785
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis Based on
Zhang Y; Wang S; Han S; Feng Y
Front Oncol; 2022; 12():844794. PubMed ID: 35359375
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of lymphocyte infiltration-associated lncRNA for ovarian cancer via TCGA, GTEx and GEO datasets.
Wu M; Shang X; Sun Y; Wu J; Liu G
PeerJ; 2020; 8():e8961. PubMed ID: 32419983
[TBL] [Abstract][Full Text] [Related]
10. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
[TBL] [Abstract][Full Text] [Related]
11. P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer.
Zhao Q; Liu J
Front Cell Dev Biol; 2021; 9():754580. PubMed ID: 34966739
[No Abstract] [Full Text] [Related]
12. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive pan-cancer analysis reveals CCDC58 as a carcinogenic factor related to immune infiltration.
Wu H; Geng Q; Shi W; Qiu C
Apoptosis; 2024 Apr; 29(3-4):536-555. PubMed ID: 38066393
[TBL] [Abstract][Full Text] [Related]
14. A Pan-Cancer Analysis Revealing the Dual Roles of Lysine (K)-Specific Demethylase 6B in Tumorigenesis and Immunity.
Ding JT; Yu XT; He JH; Chen DZ; Guo F
Front Genet; 2022; 13():912003. PubMed ID: 35783266
[No Abstract] [Full Text] [Related]
15. CCDC137 Is a Prognostic Biomarker and Correlates With Immunosuppressive Tumor Microenvironment Based on Pan-Cancer Analysis.
Guo L; Li B; Lu Z; Liang H; Yang H; Chen Y; Zhu S; Zeng M; Wei Y; Liu T; Jiang T; Xuan M; Tang H
Front Mol Biosci; 2021; 8():674863. PubMed ID: 34055889
[TBL] [Abstract][Full Text] [Related]
16. TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
Wang K; Feng X; Zheng L; Chai Z; Yu J; You X; Li X; Cheng X
Front Mol Biosci; 2021; 8():690500. PubMed ID: 34262942
[No Abstract] [Full Text] [Related]
17. Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer.
Chen J; Gao G; Li L; Ding J; Chen X; Lei J; Long H; Wu L; Long X; He L; Shen Y; Yang J; Lu Y; Sun Y
Front Genet; 2022; 13():817118. PubMed ID: 35601500
[No Abstract] [Full Text] [Related]
18. Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients.
Lu T; Li C; Xiang C; Gong Y; Peng W; Chen C
Biomed Res Int; 2022; 2022():7823191. PubMed ID: 35313629
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
